Program

 

The virtual program will be announced soon.

The originally scheduled workshop program is reflected below.

SUNDAY, APRIL 26, 2020

2:30pm-3:00Check-in/Registration
3:00–3:15Opening Remarks Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
SESSION I. DRUG DISCOVERY 2.0CHAIR: Walter Kostich, PhD—National Multiple Sclerosis Society
3:15–3:20Session Overview
3:20–3:45Omics to Identify Novel Target for Neurodegenerative Diseases Philip De Jager, MD, PhD—Columbia University
3:45–4:10Pre-clinical Science, Clinical Development and Pathway to Marketing Approval of a Living Cell Pharmaceutical for AD – the Mesenchymal Stem/Stromal Cell ParadigmJacques Galipeau, MD—University of Wisconsin, Madison
4:10–4:35Shift in Medicinal Chemistry: from Organic Chemistry to Synthetic BiologyEdmund Graziani, PhD—Apertor Labs
4:35–4:55SESSION I: PANEL DISCUSSION
5:00–5:30MENTORING SESSION (one-to-one mentoring sessions with field experts - pre-registration required)
5:00–7:00EXHIBITS AND WELCOME RECEPTION

MONDAY, APRIL 27, 2020

7:30–8:20amCheck-in and Continental Breakfast
8:20–8:30Opening Remarks and ADDF Funding Opportunities Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
8:30–8:50National Institute on Aging Alzheimer’s and Related Dementias Translational Research ProgramZane Martin, PhD—National Institute on Aging
8:50–9:00NINDS Opportunities for Translational Research Funding Charles Cywin, PhD—National Institute of Neurological Disorders and Stroke
9:00–9:40KEYNOTE: The Clinical Potential of Senolytic DrugsJames Kirkland, MD, PhD—Mayo Clinic
9:40–10:00EXHIBITS AND BREAK
SESSION II. DRUG DISCOVERY: FROM TEST TUBE TO ANIMAL STUDIESCHAIR: Nadine Tatton, PhD—The Association for Frontotemporal Degeneration (AFTD)
10:00–10:05Session Overview
10:05–10:30Compound Optimization after Target Identification: From HTS to LeadKurt Brunden, PhD—University of Pennsylvania
10:30–10:55What Can We Still Learn from Studies in Animal Models of Neurodegenerative Disease?Joseph Araujo—InterVivo Solutions
10:55–11:20Translational PK/PD in NeurodegenerationNatasha Penner, PhD—Biogen
11:20–11:40SESSION II: PANEL DISCUSSION
11:40am–12:10pmPOSTER SESSION
12:10–1:00LUNCH
SESSION III. FROM ANIMAL STUDIES TO HUMAN CLINICAL TRIALSCHAIR: Liliana Menalled, PhD—The MJFF
1:00–1:05Session Overview
1:05–1:30Requirements for an IND/ToxicologyKenneth Olivier, PhD—Biotech Primer
1:30–1:55What are Biomarkers and Why Should I Develop Them?John Gerdes, PhD—Rio Pharma
1:55–2:20How to Run a Clinical Trial?Anita DiFrancesco—Samumed
2:20–2:40SESSION III: PANEL DISCUSSION —Trends in Clinical Trials
2:40–3:10EXHIBITS AND BREAK
SESSION IV. I WISH I KNEW... (PRECLINICAL) CHAIR: Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
3:10–3:15Session Overview
3:15–3:40Case Study: Challenges in Biomarker Development for Huntington's DiseaseDouglas Macdonald, PhD—CHDI Foundation
3:40–4:05Case Study: Challenges in Drug Development for Neurodegenerative DiseaseLeticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
4:05–4:30Case Study: Development of Novel Stress Kinase InhibitorD. Martin Watterson, PhD—Northwestern University
4:30–4:55Case Study: Alzheimer’s Disease Drug Discovery: NMEs vs. NCEs, Pros and Cons of EachAllen Reitz, PhD—ALS Biopharma
4:55–5:15SESSION IV: PANEL DISCUSSION
5:15–6:15EARLY CAREER INVESTIGATOR PANEL: Discuss job opportunities in drug discovery
Moderator: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation

Foundation: Liliana Menalled, PhD—The MJFF and Kuldip Dave, PhD—The ALS Assoc.
Government: Charles Cywin, PhD—NINDS
Biotech: Edward Spack, PhD—Vector BioSolutions/Therini
Academia: D. Martin Watterson, PhD—Northwestern University
Pharma: Natasha Penner, PhD—Biogen
6:15–7:30NETWORKING RECEPTION

TUESDAY, APRIL 28, 2020

7:30–8:15Check-in and Continental Breakfast
7:30-8:00MENTORING SESSION (one-to-one mentoring sessions with field experts - pre-registration required)
8:25–8:30Welcome & Opening Remarks: ADDF
SESSION V. WORK WITH THE EXPERT - BREAKOUT SESSIONCHAIR: Elizabeth Mills, PhD—Alzheimer’s Drug Discovery Foundation
8:30–8:35Session Overview
8:35–9:45Breakouts:
1. Drug Discovery
2. Preclinical Study
3. Starting a Company/Commercialization
4. Career outside Science
5. How Do I Get Funded?
9:45–10:15EXHIBITS AND BREAK
SESSION VI. I WISH I KNEW... (CLINICAL)CHAIR: Kuldip Dave, PhD—The ALS Association
10:15–10:20Session Overview
10:20–10:45Case Study: O-GlcNAcase Inhibitors for the Treatment of Tauopathies – From Early Discovery to a Clinical Efficacy Trial in PSP PatientsDirk Beher, PhD—Asceneuron
10:45–11:10Case Study: Challenges Associated with Biomarker Development in Neurodegenerative Conditions – “A Commercial Perspective”Iswariya (Ishu) Venkataraman, PhD—Euroimmun
11:10–11:35Case Study: SEMA4D Modulates Blood-Brain Barrier, Microglia, and Inhibits Remyelination in Neurodegenerative DiseaseMaurice Zauderer, PhD—Vaccinex
11:35–12:00Case Study: TBATBA
12:00–12:20SESSION VI: PANEL DISCUSSION
12:20–12:50POSTER SESSION
12:50–1:45LUNCH
SESSION VII. BUILDING THE INFRASTRUCTURE TO COMMERCIALIZE SCIENCE INTO PRODUCTSCHAIR: Alessio Travaglia, PhD—Alzheimer's Drug Discovery Foundation
1:45–1:50Session Overview
1:50–2:15The Handling of Drug Discovery IP and Paths to CommercializationMaria Emanuel, PhD—University of New Hampshire
2:15–2:40Developing your Team and Your Funding StrategyEdward Spack, PhD—Vector BioSolutions/Therini
2:40–3:25SESSION VII: PANEL DISCUSSION—How Do I Get Funded?Moderator: Alessio Travaglia, PhD—ADDF

Panelists:
Kuldip Dave, PhD—The ALS Association
David Kemp, President—CurePSP
Walter Kostich, PhD—National Multiple Sclerosis Society
Douglas Macdonald, PhD—CHDI Foundation
Liliana Menalled, PhD—The Michael J. Fox Foundation
Andrew Pieper—Harrington Discovery Institute
Nadine Tatton, PhD—AFTD
Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
3:25–3:30Closing RemarksAlessio Travaglia, PhD—Alzheimer's Drug Discovery Foundation

SCIENTIFIC ADVISORY COMMITTEE

Kurt Brunden, PhD—University of Pennsylvania
Kuldip Dave, PhD—ALS Association
Howard Fillit, MD—ADDF
Lauren Friedman, PhD—ADDF
Marcie Glicksman, PhD
Walter Kostich, PhD—National MS Society
Frank Longo, MD, PhD—Stanford University
Suzana Petanceska, PhD—NIH/NIA
Edward Spack, PhD—Vector BioSolutions/Therini
Alessio Travaglia, PhD—ADDF
D. Martin Watterson, PhD—Northwestern University